Diamyd Logo

Clinical trials

Drug development is a very long and costly process. It is said that in general it costs one billion USD to take a drug from discovery to market. A candidate drug must get through a number of stages, before it can obtain a market approval.


Diamyd Medical's research in the area of diabetes originates from the GAD65 molecule. Since the mid-1990s, the Company has completed several clinical trials with GAD65.

At this time two researcher initiated clinical studies with Diamyd® are in progress: A Swedish Phase II prevention study, DiAPREV-IT, aiming to evaluate whether Diamyd® can prevent or delay type 1 diabetes in children who are at high risk of developing the disease and; a Swedish Phase II combination study, DIABGAD-1, where Diamyd® is tested in a unique combination with relatively high doses of vitamin D and the anti-inflammatory drug ibuprofen in newly diagnosed type 1 diabetes children and adolescents, aiming to potentiate the effect of the Diamyd® diabetes vaccine to preserve the body´s own ability to control the blood sugar level.